BIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug; Pfizer’s gene therapy setback; Foresite’s $900M fund

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Antioxidant-rich diets linked to lower type 2 diabetes risk, supplements less effective

Study systematically reviews the impact of dietary antioxidants, vitamins C, E, and beta-carotene, on reducing the risk of type 2 diabetes, suggesting an inverse association

March 26, 2024

FDA advisory committee says risks of Novo Nordisk’s once-weekly insulin outweigh benefits in type 1 diabetes patients

An FDA advisory committee on Friday voted not to recommend Novo Nordisk’s once-weekly insulin injection in type 1 diabetes patients. Novo has pitched its candidate

May 25, 2024

From the newsroom: Endpoints wins a SABEW award for general excellence

On Thursday, Endpoints News won a general excellence award from the Society for Advancing Business Editing and Writing, and was a finalist in another category

March 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.